Eric Halioua, our CEO, will give a company presentation and be part of the Advances in Immuno-Oncology Panel at the SACHS FORUM 14th Annual European Life Sciences CEO Forum. He will also give a...
We are very pleased to announce the publication in Vaccines of a new article describing the capability of our Engineered PDC*line Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen...
We are pleased to announce that our CEO Eric Halioua will present PDC*line Pharma strategy and innovative vaccinal platform on January 21, 2021 at LINK-J's inaugural Advanced Therapy Showcase in Tokyo...
PDC*line Pharma team wishes you and your loved ones a festive & healthy holiday season and a successful 2021!
Have a look at the interview of PDC*line Pharma 's CEO Eric Halioua by Andrew McConaghie a journalist of SCRIP in an on-demand "Fireside Chat" session during the BIOEUROPE FALL 2020. He presents the...
Eric Halioua, President & CEO of PDC*line Pharma will be today, Nov. 2nd 2020, a panelist in a round table on Therapeutic Cancer vaccines and make a company presentation at the Festival of Biologics v...
PDC*line Pharma, a biotech company developing a novel class of potent and off-the-shelf cancer immunotherapies to treat cancer patients, today announced that the Company will give presentations and...
Cohorts A2 (single agent high dose in adjuvant setting) and B1 (low dose added to anti-PD-1) have been opened and first patient of cohort A2 has been dosed
Liège, Belgium and Grenoble, France...
We are very pleased to announce that PDC*line Pharma is one of the three nominees for the 2020 BVA Award Venture company of the year!
THE BELGIAN VENTURE CAPITAL & PRIVATE EQUITY ASSOCIATION...
PDC*line Pharma strengthens its board of directors with an
industry leader in the field of immuno-oncology
Liège, Belgium and Grenoble, France, June 25, 2020 – PDC*line Pharma, a clinical stage...
